Politics Helen Branswell, Rachel Cohrs and Damian Garde STAT Plus: 8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel
The Obesity Revolution Isabella Cueto and Theresa Gaffney ‘That scares me’: New childhood obesity guidelines still face a long road to consensus
Pharmalot Ed Silverman STAT Plus: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%
Pharmalot Ed Silverman STAT Plus: Here’s why there aren’t many cheap, generic versions of pricey inhalers
Pharmalot Ed Silverman STAT Plus: U.K. trade group suspends Novo Nordisk for ‘serious breaches’ in promoting obesity drug
Health Sean Murphy and Matthew Perrone — Associated Press Texas judge hears arguments in lawsuit to pull long-used abortion pill off the market
Politics Sarah Owermohle STAT Plus: Senators interrogate health secretary Becerra on Alzheimer’s drug coverage
Pharmalot Ed Silverman STAT Plus: Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH won’t seize patents to cut price of cancer drug
Health Angus Chen Study finds same small rise in breast cancer risk in many forms of hormonal birth control
Pharmalot Ed Silverman STAT Plus: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
Biotech Allison DeAngelis STAT Plus: Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
Health Nicholas Florko STAT Plus: Arizona plans to dramatically increase hepatitis C testing and treatment in prisons
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too little on drug research
Pharma Adam Feuerstein STAT Plus: French pharma Sanofi buys maker of diabetes treatment for $2.9 billion
Pharma Adam Feuerstein STAT Plus: Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion
Pharmalot Ed Silverman STAT Plus: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap
First Opinion Alfred Engelberg STAT Plus: Clearing the patent thicket: A pathway to faster generic drug approvals
Politics Rachel Cohrs STAT Plus: An unlikely new 340B alliance emerges between PhRMA and community health centers
Politics Rachel Cohrs STAT Plus: Pfizer CEO Albert Bourla maxed out campaign contributions to Dr. Oz ahead of midterm elections
Health Tech Ben Brody STAT Plus: ‘Truth is losing the battle’: FDA commissioner on grappling with a wave of health misinformation
Pharmalot Ed Silverman STAT Plus: Controversial drug for premature birth is withdrawn by manufacturer after battle with FDA
Politics Andrew Joseph STAT Plus: Q&A: Califf on obesity drugs, advisory panels, and how threats hurt recruitment at FDA
Pharma Matthew Herper STAT Plus: After its drug was shown to prevent heart attacks, what’s next for Esperion?
Politics John Wilkerson STAT Plus: By cutting insulin prices, Eli Lilly avoids paying big Medicaid rebates
The Obesity Revolution Elaine Chen and Matthew Herper STAT Plus: New weight loss drugs are changing the narrative on obesity, with a push from pharma